A Phase III Trial of AZD0780 on Major Adverse CV Events
Phase 3
15,100
about 4.4 years
18+
293 sites in AL, AZ, CA +38
What this study is about
Researchers are testing whether AZD0780, a medication, reduces the risk of major adverse cardiovascular events (MACE) in people who have already had heart problems or are at high risk for developing them. The trial will last 1605 days and involve approximately 15100 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take AZD0780
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Time to first event of any component of MACE-PLUS
Secondary: Time to first event of any component of 3P MACE, Time to first event of any component of MACE PLUS
Cardiology / Heart